MedTrace Logo

Feasibility and Effectiveness of a Personalized Inpatient Program for Persistent Depressive Disorder

NCT03616665 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-09-14

No results posted yet for this study

Summary

The major objective of this study is to evaluate a new conceptualized personalized concept of Cognitive Behavioral Analysis System of Psychotherapy (CBASPersonalized) in the treatment of patients with persistent depressive disorder (PDD), childhood maltreatment and a high rate of comorbidity. Patients receive a two-phase-treatment-program (six-weeks inpatient-treatment and six-to-twelve-weeks blended-online-aftercare) in combination with standardized pharmacotherapy in a routine clinical inpatient setting. This study addresses the primary research question: Is an intensive six-week inpatient CBASPersonalized treatment feasible and effective in a clinical sample of PDD patients? In addition, moderator, process and long-term analyses will be conducted for differential insights.

Conditions

  • Persistent Depressive Disorder

Interventions

OTHER

CBASPersonalized

In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses. After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home. Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented.

Sponsors & Collaborators

  • Schön Klinik Bad Arolsen

    collaborator UNKNOWN

  • Philipps University Marburg

    lead OTHER

Principal Investigators

  • Eva-Lotta Brakemeier, Prof. Dr. · University Greifswald and Philipps University Marburg

  • Jörg-Tobias Hof · Schön Klinik Bad Arolsen (study site)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-12-31
Completion
2021-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03616665 on ClinicalTrials.gov